#Ireland #Galway #CE Mark #InVera Medical #vein infusion

InVera Medical Secures European CE Mark Approval for Innovative Vein Device

In a monumental achievement for the medical technology field, InVera Medical, based in Galway, Ireland, has recently been awarded the esteemed European CE Mark for its new vein infusion device. This new apparatus is specifically engineered to address the intricacies involved in treating chronic venous diseases, including prevalent conditions such as varicose veins. Notably, the path to this regulatory approval marks a significant milestone, paving the way for improved therapeutic options in the European medical landscape.

The InVera Infusion Device: A Breakthrough in Treatment

The InVera Infusion Device stands out from its competitors by utilizing a minimally invasive approach that does not rely on thermal energy to treat affected veins. Traditional treatments often involve burning the vein, but InVera's innovative design enables a procedure that can be performed conveniently within a doctor's office. Patients require only a localized anesthetic, eliminating the need for extensive surgical setups typically seen in hospitals.

This advancement signifies a substantial leap towards providing physicians with a more diverse set of non-thermal interventions for managing Chronic Venous Disease (CVD). The device employs a slender catheter, which is precisely inserted guided by ultrasound technology – a technique familiar to most medical professionals. This design aims to facilitate a more efficient infusion of therapeutic agents directly into the affected veins, thus enhancing the effectiveness of the treatment.

Addressing a Significant Healthcare Gap

Chronic Venous Disease is a widespread condition affecting nearly 25% of adults, and, if untreated, it can escalate into more severe complications, including painful leg ulcers. Alarmingly, statistics reveal that while over 120 million individuals in Europe and the United States are estimated to suffer from venous disease, fewer than 1% undergo interventional treatments annually. This stark discrepancy highlights a considerable gap in the care available to patients, one that InVera Medical intends to bridge.

Stephen Cox, the CEO and Co-Founder of InVera Medical, emphasized the importance of this CE Mark approval. He stated, “Securing the CE Mark is a crucial milestone for InVera Medical and a step forward in bringing this technology closer to patients across Europe. Our focus has been to develop a less-invasive, effective approach perfectly compatible with existing clinical practices, enhancing both the treatment experience for physicians and their patients.”

A Commitment to Innovation and Patient Care

Since its founding in 2018, InVera Medical has dedicated itself to the development of catheter-based technologies aimed at treating vein diseases. The company prides itself on a patient-first mission, promising a scientific approach that prioritizes the safety and effectiveness of medical devices. The InVera Infusion Device is now CE Marked and cleared for use within the European Union; however, it has yet to be made available in the United States or other global markets.

As the healthcare sector continues to evolve, innovations such as the InVera Infusion Device exemplify a shift towards more efficient and patient-friendly treatment options. The availability of such advanced technology not only enhances patient outcomes but also fosters a new era in the management of chronic venous conditions, showing promise for patients who have long awaited effective solutions.

For further inquiries or more details on InVera Medical’s innovative solutions, you can visit their official website at www.inveramedical.com.